Articles On Recce Pharmaceuticals (ASX:RCE)

Title Source Codes Date
Recce Pharmaceuticals expands COVID-19 screening program via US-based study

One week since announcing two of its compounds will be used in an upcoming antiviral SARS-CoV-2 screening program, Recce Pharmaceuticals (ASX: RCE) has penned an agreement with US-based precision medicine company Path BioAnalytics for the s...

SmallCaps RCE 3 years ago
Why the Recce Pharmaceuticals share price just rocketed 31% higher to a record high

One of the best performers on the Australian share market on Thursday has been the Recce Pharmaceuticals Ltd (ASX: RCE) share price. This morning the pharmaceutical company’s shares rocketed a massive 31% higher to a record high $1.50. Whe...

Motley Fool RCE 3 years ago
Why PointsBet, Recce Pharmaceuticals, Vocus, & Webjet shares are storming higher

In late morning trade the S&P/ASX 200 Index (ASX: XJO) has given back its early gains and is dropping slightly lower. At the time of writing the benchmark index is down a few points to 6,050.2 points. Four shares that have not let that...

Motley Fool RCE 3 years ago
2 ASX shares that could be 10-baggers

I think that if you are going to make serious money on the share market, then you have to find 1 or 2 companies for your portfolio that enjoy rapid growth. These preferably shouldn’t make up a large percentage of your portfolio, but are st...

Motley Fool RCE 3 years ago
Scopo’s health powerplays: The cash caboose keeps rolling on

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week The life s...

Stockhead RCE 3 years ago
2 breakthrough ASX healthcare shares

The Australian medical sector has been one of the great drivers of innovation in global health for decades. For example, Australians created the electronic pacemaker. In addition, together with Alexander Fleming, we helped pioneer the life...

Motley Fool RCE 3 years ago
S&P/ASX 200 (XJO) today – APT, PPS & TWE shares in focus

The S&P/ASX 200 (INDEXASX: XJO) is expected to take a backwards step at the open this morning according to data from the Sydney Futures Exchange. Here’s what you need to know. Afterpay: the NASDAQ effect It was another volatile day for...

Rask Media RCE 3 years ago
Closing Bell: Today’s biggest small cap movers on the ASX

A quick wrap of the ASX’s key winners and losers on Thursday, July 9. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made market-moving announcements during the day. Today 832 stocks rose, 502 declined and 77...

Stockhead RCE 3 years ago
Recce Pharmaceuticals Shares Up on Possible COVID-19 Treatment

That’s where biotech companies like Recce Pharmaceuticals Ltd [ASX:RCE] come in. A small-cap that is trading 50% higher today after it was selected to see if it could help fight the coronavirus.... The post Recce Pharmaceuticals Shares Up o...

MoneyMorning RCE 3 years ago
Recce Pharmaceuticals’ formulations to be evaluated as potential treatment for COVID-19

Recce Pharmaceuticals (ASX: RCE) emerged from a trading halt to announced that two of its drug candidates would be used in an upcoming antiviral SARS-Cov-2 screening program. The pharma company is attempting to develop and commercialise new...

SmallCaps RCE 3 years ago
10 at 10: These ASX stocks are an awestriking sight this morning

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Stockhead RCE 3 years ago
Recce announces COVID-19 research agreement

Sydney-based anti-infective company Recce Pharmaceuticals (ASX:RCE) has announced an Antiviral SARS-CoV-2 Screening Program Agreement with CSIRO and the University of Melbourne's Doherty...

BiotechDispatch RCE 3 years ago
Recce share price on watch following COVID-19 antiviral selection

The Recce Pharmaceuticals Ltd (ASX: RCE) share price is on watch today after the company announced it has entered into an antiviral Sars-CoV-2 screening program. Recce (pronounced ‘recky’) is pioneering a new class of synthetic antibiotics...

Motley Fool RCE 3 years ago
Michele Dilizia from Recce Pharmaceuticals Ltd (ASX:RCE)

Recce Pharmaceuticals (RCE) Executive Director Michele Dilizia joins Peter Switzer.

Switzer RCE 3 years ago
Bondi backpackers rejoice! Recce may have a gonorrhoea cure

Backpackers in Bondi were pilloried for spreading COVID-19, but everyone knows gonorrhoea is a greater risk in the suburb’s sandy stews. Antibiotic maker Recce Pharmaceuticals (ASX: RCE) says its lead candidate is proving to be effective ag...

Stockhead RCE 4 years ago
Bugkillers: These 2 stocks upped the ante in their bug battles this morning

COVID-19 may seem the only bug worth seeking to squash right now but there are at least two other battles that haven’t witnessed a ceasefire. One prominant group of bugs are the so-called “super bugs” — bacteria which as its name suggests c...

Stockhead RCE 4 years ago
Recce Pharma reports positive data from anti-viral drug trial for Influenza A, signs agreement for first-in-human study

A study into a new class of synthetic antibiotics developed by Recce Pharmaceuticals (ASX: RCE) has produced positive data showing significant in vivo anti-viral activity against Influenza A virus in mice being treated with the company’s pa...

SmallCaps RCE 4 years ago
Health: Even bacteria fighter Next Science is feeling the coronavirus pinch

While we need all the bacteria fighters we can get right now, they are not immune to the coronovirus panic and Next Science (ASX:NXS) is the latest to admit it hasn’t been able to escape the impact. The company, which listed last April and...

Stockhead RCE 4 years ago
Recce Pharmaceuticals updates on move to trial of antibiotic

Sydney-based Recce Pharmaceuticals (ASX:RCE), a company developing a new class of broad-spectrum synthetic antibiotics, has updated on progress to begin the first human trials of its lead compound RECCE 327.

BiotechDispatch RCE 4 years ago
Recce Pharmaceuticals’ (ASX:RCE) positive data from RECCE 327 indicates wide dosage window

Recce Pharmaceuticals (RCE) has announced positive data from its RECCE 327 antibiotic study on rats and dogs RECCE 327 is addressing the increasing threat of superbugs that are resistant to antibiotics Studies indicated that various dosage...

themarketherald.com.au RCE 4 years ago
Bug killers: Zoono has become a 13-bagger in 4 months as China seeks a coronavirus solution

Since mid-October Zoono (ASX:ZNO) has climbed from 8.2c to $1.20 this morning — a 1,382 per cent spike. And it is still climbing after more good news this morning. The antimicrobial solution maker unveiled its latest distribution agreement...

Stockhead RCE 4 years ago
Sepsis has tripled in Australia and these small caps are tackling it head on

With triple the number of sepsis cases in Australia, small cap biotech company Cynata Therapeutics (ASX:CYP) hopes to wage a new war on blood infections. Last Friday the world learned blood infections were on the rise, with researchers show...

Stockhead RCE 4 years ago
Reward Minerals to discuss Australia’s largest brine SOP deposit at Proactive’s Sydney CEO Session

Also presenting at the CEO Sessions will be Great Boulder Resources, Recce Pharmaceuticals and Antisense Therapeutics.

Proactive Investors RCE 4 years ago
Recce Pharmaceuticals to talk new class of synthetic antibiotics at Proactive’s CEO Sessions

Five companies will present at Proactive’s CEO Sessions in Sydney on February 3 and Melbourne on February 4.

Proactive Investors RCE 4 years ago
The most noteworthy directors trades of 2019

Every week Stockhead publishes a weekly column of directors trades of $100,000 or more among ASX small caps. As 2019 draws to a close, we thought we could re-cap the most noteworthy trades.   Biggest trade Wagners (ASX:WGN) co-founders Deni...

Stockhead RCE 4 years ago
Health Kick Podcast: Commercialising orphan drugs, the need for better regulation and the ASX’s lifestyle play problem

Stockhead’s resident Health and Biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment of The Health Kick Podcast. In this episode Tim chats with Race Oncology (ASX:RCE) CEO Peter Mol...

Stockhead RCE 4 years ago
Is Downer a good deal among Industrial stocks – DOW, REH, QUB, ALQ, CWY

Industrial Sector or the secondary sector of the economy processes raw materials / inputs provided by other sectors into manufactured goods and finished products. Some economists are of the view that manufacturing industry generates more we...

Kalkine Media RCE 4 years ago
Health Talk: IBX, CYC, VLS, RCE, VHT, NXS

In the Australian health care system, three levels of government are responsible for providing universal health care- federal government, state and territory government and local government. Funding and indirect support are provided by the...

Kalkine Media RCE 4 years ago
Health: Fricken lasers shrink ovarian cancer (also look good on sharks)

For a certain generation of investors the word ‘laser’ is indelibly tied to a Dr Evil reference. Over the last two years Invion (ASX:IVX) has been valiantly working against this association, and today says its lasers (not attached to the he...

Stockhead RCE 4 years ago
Asian investors are targeting Aussie stocks. Here’s what they’re aiming for

E-sports, technology, biotech and primary producer stocks are all experiencing growing interest from Asian investors. This partially reflects rising investor sophistication, as well as the chance to pursue Australian investments in sectors...

Stockhead RCE 4 years ago
Rise & Shine: What you need to know before the ASX opens

On Stockhead today: five water treatment stocks surge 260 per cent in a year, the ASX’s most intriguing bargain barrel stocks, the five 2019 IPO stocks delivering triple returns and Dorado-3 oil flow gets Carnarvon on track. But first:   Th...

Stockhead RCE 4 years ago
Shaws beats drum for Recce Pharma placement

Synthetic antibiotics developer Recce Pharmaceuticals has tasked Shaw and Partners with raising fresh funds for the company on Tuesday. 

AFR RCE 4 years ago
Shaw and Partners appointed as Lead Manager to the equity capital raising by Recce Pharmaceuticals

Shaw and Partners has been appointed as Lead Manager to an equity capital raising by Recce Pharmaceuticals Limited (RCE).   RCE is undertaking a placement of approx. 15.5... Read More

Shaws RCE 4 years ago
Stocks Charting Higher on ASX – CCA, GBE, RCE, ZNO, FHS

Publicly traded companies lay great emphasis on their respective share price, which mirrors their overall financial health. Analysts, media houses and industry experts vigilantly gauge at the stocks riding high on stock exchanges. Typically...

Kalkine Media RCE 4 years ago
Recce Pharmaceuticals to benefit from $5 million in government funds for AMR Research Hub

The company is pioneering the development of a new class of synthetic antibiotics with broad-spectrum activity, designed to address the problem of antibiotic superbugs.

Proactive Investors RCE 4 years ago
Director’s Trades: Everyone’s on holidays except those dreaming of one

This week only six directors traded $100,000 or more. So we’ve also recapped some big directors’ trades from earlier this year seeing if they paid off – including that millennial director who spent $100,000 on his company rather than a hous...

Stockhead RCE 4 years ago
Marijuana skin cream kills superbugs, says Botanix

Pot stock Botanix (ASX:BOT) says one of its cannabis formulations kills superbugs — in animals and in the lab. Botanix is better known to investors as a biotech developing cannabis-based medications for skin conditions, but it also has a re...

Stockhead RCE 4 years ago